| |
|
|
|
|
|
|
|||
|
Blood, 1 February 2007, Vol. 109, No. 3, pp. 1123-1130. Prepublished online as a Blood First Edition Paper on September 28, 2006; DOI 10.1182/blood-2006-04-019711.
IMMUNOBIOLOGY Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function1 Department of Developmental & Molecular Pathways, Novartis Institute for BioMedical Research (NIBR), Cambridge, MA; and 2 Department of Genome and Proteome Sciences, NIBR, Cambridge, MA Histone deacetylases (HDACs) play a critical role in regulating gene expression and key biological processes. However, how HDACs are involved in innate immunity is little understood. Here, in this first systematic investigation of the role of HDACs in immunity, we show that HDAC inhibition by a small-molecule HDAC inhibitor (HDACi), LAQ824, alters Toll-like receptor 4 (TLR4)dependent activation and function of macrophages and dendritic cells (DCs). Surprisingly, pan-HDAC inhibition modulates only a limited set of genes involved in distinct arms of immune responses. Specifically, it inhibited DC-controlled T helper 1 (Th1) effector but not Th2 effector cell activation and migration. It also inhibited macrophage- and DC-mediated monocyte but not neutrophil chemotaxis. These unexpected findings demonstrate the high specificity of HDAC inhibition in modulating innate and adaptive immune responses, and highlight the potential for HDACi to alter the Th1 and Th2 balance in therapeutic settings.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||